Recent Updates
Recently added Catalysts
PHIO Positive Sentiment

Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Thursday, August 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Phio Pharmaceuticals has reported significant advancements in its lead clinical candidate PH-762 during the second quarter of 2026. Key milestones include the initiation of commercial scale active pharmaceutical ingredient (API) production, completion of Phase 1b pharmacology studies, and announcements of new intellectual property. The company continues to progress in its development of therapeutics using its INTASYL® gene silencing technology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Advancements in lead clinical candidate PH-762.
  • Initiation of commercial scale API.
  • Completion of Phase 1b pharmacology.
  • New intellectual property announcements.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~10 mo
Medium dilution risk
Lead asset
DP CD8 TIL
Phase 1 · HNSCC

Full Press Release Details

Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase 1b pharmacology, and new IP announcements King of Prussia, Pennsylvania–(Newsfile Corp. – August 6, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing […]
The post Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update appeared first on Phio Pharmaceuticals .

Frequently Asked Questions

What are the key milestones reported by Phio Pharmaceuticals?

Phio Pharmaceuticals reported advancements in PH-762, including API production and Phase 1b completion.

What is the significance of the new IP announcements?

The new intellectual property announcements enhance Phio's competitive position in gene silencing.

Where is Phio Pharmaceuticals located?

Phio Pharmaceuticals is based in King of Prussia, Pennsylvania.

What technology does Phio Pharmaceuticals use?

Phio Pharmaceuticals develops therapeutics using its proprietary INTASYL® gene silencing technology.

ShareAdd on Google
Tags: PHIO Viatris Investor Conferences Healthcare PH-762 gene silencing clinical-stage biopharmaceutical
Last updated: Aug 6, 2026

Biotech snapshot

Cash runway
$17M liquidity · $1M/mo burn
~10 mo
Medium dilution risk
Lead asset
DP CD8 TILPhase 1
HNSCC →